Copyright: ©Author(s) 2026.
World J Clin Cases. Mar 16, 2026; 14(8): 118582
Published online Mar 16, 2026. doi: 10.12998/wjcc.v14.i8.118582
Published online Mar 16, 2026. doi: 10.12998/wjcc.v14.i8.118582
Table 1 Summary of baseline characteristics of the included studies, mean ± SD
| Ref. | Study design | Sample size (n) | Age in years | Dose (mg/kg) | Number of males, n (%) | SBP, mmHg | DBP, mmHg | Oxygen saturation (%) | Heart rate, bpm | MAP, mmHg | |||||||||
| Control | Interv | Control | Interv | Control | Interv | Control | Interv | Control | Interv | Control | Interv | Control | Interv | Control | Interv | Control | Interv | ||
| Ferguson et al[17], 2016 | RCT | 292 | 281 | 46 ± 23.84 | 50 ± 25.3 | 1 mg/kg propofol | 1:1 ketofol = 0.25 | 145 ± 49 | 138 ± 49 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Miner et al[22], 2014 | RCT | 90 | 1:1 ketofol = 85; 4:1 ketofol = 96 | 40 ± 17.05 | 1:1 = 39 (17.8); 4:1 = 36 (16) | 1 mg/kg propofol | 1:1 ketofol = propofol - 0.5 mg/kg, ketamine - 0.5 mg/kg, 4:1 ketofol = propofol - 0.8 mg/kg, ketamine - 0.2 mg/kg | 47 ± 52 | 1:1= 45 ± 53; 4:1= 51 ± 53 | 127 ± 51.15 | 1:1 = 127 ± 17.79; 4:1 = 129 ± 14.83 | NR | NR | 100 | 1:1 = 100; 4:1 = 100 | NR | NR | NR | NR |
| Ulutas et al[32], 2023 | RCT | 34 | 30 | 53.65 ± 14.57 | 46.27 ± 18.72 | 1 mg/kg propofol | 1:1 ketofol = 0.5 mg/kg ketamine + 0.5 mg/kg propofol | 25 ± 73.5 | 18 ± 60 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Soliman et al[25], 2017 | RCT | 30 | 30 | 14.48 ± 1.26 | 14.09 ± 1.32 | A bolus dose of propofol (1-2 mg/kg) and then a contin | 1:1 ketofol = 1 mg/kg as a bolus dose and continu | 16 ± 53.53 | 13 ± 43.33 | NR | NR | NR | NR | NR | NR | 79.9 ± 7.5 | 79.0 ± 6.9 | 85.3 ± 6.9 | 85.1 ± 6.6 |
| Kumar et al[26], 2020 | RCT | NR | NR | NR | NR | 1.5-2.5 mg/kg propofol | IV ketamine 1 mg/kg followed by propofol 1-2 mg/kg | NR | NR | NR | NR | NR | NR | NR | NR | 84.7 ± 11.9 | 81.1 ± 9.7 | 95.6 ± 11.8 | 94.6 ± 9.1 |
| Andol | RCT | 142 | 142 | 54 ± 24.47 | 48 ± 30.39 | 0.75 mg/kg of propofol | 1:1 ketofol = 0.188 mg/ kg each of ketamine and propofol | 69 ± 49 | 71 ± 50 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Tandon et al[24], 2014 | RCT | 135 | 135 | 47 ± 13 | 49 ± 12 | Propofol | Ketamine and propofol | 104 ± 77.03 | 100 ± 74.04 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Khalil et al[35], 2021 | RCT | 53 | 53 | 26.49 ± 3.06 | 27.68 ± 3.67 | Propofol (2 mg/kg) | Propofol (1 mg/kg) plus ketamine (0.5 mg/kg) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Frey et al[23], 1999 | RCT | 33 | 33 | NR | NR | Propofol | 3.3:1 ketofol | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Cui et al[27], 2023 | RCT | 67 | 68 | 65.6 ± 10.2 | 62.9 ± 9.6 | Propofol | Esketam | 42 ± 62.7 | 34 ± 50 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Liu et al[28], 2025 | RCT | 126 | 126 | 65 ± 10.38 | 64.5 ± 11.12 | 1 mg/kg propofol | 1 mg/kg propofol and 0.2 | 61 ± 48.4 | 69 ± 54.8 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Zheng et al[29], 2023 | RCT | 52 | 52 | 41.1 ± 7.9 | 42.2 ± 9.3 | 2 mg/kg propofol | 2 mg/kg propofol and 0.25 | 34 ± 65.38 | 32 ± 61.53 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Fu et al[19], 2024 | RCT | 25 | 25 for all ratios of esketofol | 54.4 ± 2.7 | 5:1 esketofol = 49.88 ± 2.6; 3.3:1 esketofol = 48.9 ± 2.4; esketofol = 1.5:1 = 48.5 ± 3.0 | 2 mg/kg propofol | 5:1 = propofol 1 mg/kg with esketam | 10 ± 40 | 5:1 = 11 ± 27.5; 3.3:1 = 12 ± 48; 1.5:1 = 16 ± 64 | 129.12 ± 21.58 | 5:1 = 127.04 ± 23.43; 3.3:1 = 126.0 ± 19.36; 1.5:1 = 120.84 ± 20.11 | 78.52 ± 16.35 | 5:1 = 78.76 ± 13.58; 3.3:1 = 78.12 ± 13.41; 1.5:1 = 75.56 ± 17.64 | 99.76 ± 0.52 | 5:1 = 99.56 ± 1.04; 3.3:1 = 99.44 ± 1.08; 1.5:1 = 99.56 ± 1.50 | NR | NR | 95.00 ± 17.06 | 5:1 = 92.16 ± 14.14; 3.3:1 = 92.96 ± 14.12; 1.5:1 = 89.12 ± 17.28 |
| Beyoğlu et al[33], 2020 | RCT | 41 | 34 | 3.23 ± 1.62 | 3.33 ± 1.77 | 1 mg/kg propofol | Ketofol | 19 ± 46.34 | 21 ± 61.76 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Frizelle et al[21], 1997 | RCT | 20 | 20 | 59 ± 13 | 55 ± 17 | Bolus of 0.5 | Initial bolus of 0.4 mg/kg propofol and 0.1 mg/kg ketamine followed by continu | 16 ± 80 | 16 ± 80 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Bhardwaj et al[30], 2024 | RCT | 29 | 29 | 24 ± 13.34 | 30 ± 22.24 | Propofol 0.5 mg/kg bolus | 1 mg/kg of ketamine and 0.5 mg/kg propofol | 19 ± 65.51 | 17 ± 58.6 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Schmitz et al[31], 2018 | RCT | 167 | 169 | 3.67 ± 3.26 | 3.91 ± 3.11 | 1 mg/kg propofol | Propofol 0.5 mg/kg and ketamine 1 mg/kg | 89 ± 53.3 | 86 ± 52.4 | NR | NR | NR | NR | 98 ± 0.74 | 98 ± 1.48 | NR | NR | NR | NR |
| Chiaretti et al[20], 2011 | RCT | 62 | 59 | 7.3 ± 5.2 | 6.9 ± 5.4 | 2 mg/kg propofol | 2 mg/kg propofol and 0.5 mg/kg ketamine | 32 ± 51 | 27 ± 44 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Xu et al[43], 2024 | RCT | 42 | 42 | 4.1 ± 1.4 | 4.2 ± 1.1 | 10 mg/mL propofol | 10:1 esketofol (propofol and esketam | 17 ± 40.47 | 11 ± 26.19 | 108 ± 13 | 105 ± 11 | NR | NR | NR | NR | 105 ± 16 | 102 ± 16 | 66 ± 12 | 63 ± 12 |
Table 2 Summary of outcomes reported by each study, mean ± SD, n (%)
| Ref. | Desaturation | Apnea | Occurrence of any respiratory intervention | Hypotension | Patient satisfaction with sedation | Recovery time (minutes) | Vomiting | ||||||||
| Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | ||
| Ferguson et al[17], 2016 | 23 ± 8 | 17 ± 6 | 16 ± 5 | 11 ± 4 | 47 ± 16 | 38 ± 14 | 24 ± 8 | 3 ± 1 | 10 ± 0 | 10 ± 0 | NR | NR | 8 ± 3 | 12 ± 4 | |
| Miner et al[22], 2014 | NR | NR | 14 ± 16 | 1:1 = 10 ± 12; 4:1 = 15 ± 16 | 41 ± 45 | 1:1 = 33 ± 39; 4:1 = 48 ± 50 | NR | NR | 70 ± 78 | 1:1 = 61 ± 72, 4:1 = 78 ± 81 | 6 ± 4.45 | 1:1 = 10 ± 8.89; 4:1 = 8 ± 8.15 | NR | NR | |
| Ulutas et al[32], 2023 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Soliman et al[25], 2017 | NR | NR | NR | NR | NR | NR | 3 ± 10 | 2 ± 6.6 | NR | NR | 26.3 ± 4.1 | 21.4 ± 3.7 | NR | NR | |
| Kumar et al[26], 2020 | NR | NR | NR | NR | NR | NR | 18 ± 60 | 3 ± 10 | NR | NR | NR | NR | NR | NR | |
| Andolfatto et al[18], 2012 | 36 ± 25 | 38 ± 27 | 13 ± 9 | 15 ± 11 | NR | NR | 1 ± 0.7 | 0 | NR | NR | 6 ± 4.45 | 8 ± 2.22 | NR | NR | |
| Tandon et al[24], 2014 | NR | NR | NR | NR | 19 ± 14.6 | 4 ± 3 | 16 ± 12 | 6 ± 4 | NR | NR | 5 ± 2.22 | 4 ± 12.22 | NR | NR | |
| Khalil et al[35], 2021 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Frey et al[23], 1999 | NR | NR | NR | NR | 18 ± 54.5 | 9 ± 27 | NR | NR | NR | NR | NR | NR | NR | NR | |
| Cui et al[27], 2023 | NR | NR | NR | NR | NR | NR | 14 ± 20.9 | 11 ± 16.2 | 10 | 10 | 6 ± 1.48 | 6 ± 0.74 | NR | NR | |
| Liu et al[28], 2025 | NR | NR | NR | NR | NR | NR | 46 ± 36.5 | 18 ± 14.3 | NR | NR | NR | NR | NR | NR | |
| Zheng et al[29], 2023 | NR | NR | NR | NR | NR | NR | 12 ± 23.1 | 4 ± 7.7 | NR | NR | NR | NR | 0 | 0 | |
| Fu et al[19], 2024 | 1 ± 4.0 | For all mixtures of esketofol = 0 | NR | NR | NR | NR | 15 ± 60.0 | Propofol + esketamine 0.2 = 4 ± 16.0; propofol + esketamine 0.3 = 4 ± 16.0; popofol + esketamine 0.4 = 3 ± 12.0 | 5.0 | For all mixtures of esketofol = 5.0 | NR | NR | NR | NR | |
| Beyoğlu et al[33], 2020 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 26.9 ± 6.19 | 27.1 ± 5.41 | NR | NR | |
| Frizelle et al[21], 1997 | NR | NR | 0 | 1 | NR | NR | 4 ± 20 | 4 ± 20 | NR | NR | NR | NR | NR | NR | |
| Bhardwaj et al[30], 2024 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 26.9 ± 6.19 | 27.1 ± 5.41 | NR | NR | |
| Schmitz et al[31], 2018 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 54 ± 29.65 | 38 ± 31.87 | 4 ± 2.5 | 3 ± 1.9 | |
| Chiaretti et al[20], 2011 | 3/62 ± 4.8 | 1/59 ± 1.7 | NR | NR | NR | NR | NR | NR | NR | NR | 20 ± 2 | 8 ± 2 | NR | NR | |
| Xu et al[43], 2024 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
Table 3 Summary of outcomes reported by each study, mean ± SD, n (%)
| Ref. | SBP (mmHg) | DBP (mmHg) | MAP at different time points, T1, T2, and T3, (mmHg) | Heart rate at time points H1, H2, H3 (beats/minutes) | Airway events | Hallucinations | ||||||
| Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | Intervention | |
| Ferguson et al[17], 2016 | NR | NR | NR | NR | NR | NR | NR | NR | 34 ± 12 | 27 ± 9 | 46 ± 15 | 100 ± 35 |
| Miner et al[22], 2014 | NR | NR | NR | NR | NR | NR | NR | NR | 19 ± 21 | 1:1 = 10 ± 12; 4:1 = 25 ± 26 | NR | NR |
| Ulutas et al[32], 2023 | t1 = 140.23 ± 2.75, t2 = 143.61 ± 26.40, t3 = 143.79 ± 27.65 | t1 = 131.06 ± 1.71; t2 = 157.53 ± 2.83 t3 = 156.46 ± 24.37 | t1 = 83.64 ± 10.86 t2 = 89.47 ± 16.69 t3 = 86.70 ± 16.71 | t1 = 72.36 ± 9.07; t2 = 92.50 ± 17.67; t3 = 83.96 ± 12.69 | t1 = 102.51 ± 13.24; t2 = 107.52 ± 16.88; t3 = 105.74 ± 18.07 | t1 = 91.93 ± 9.52; t2 = 114.18 ± 18.32; t3 = 108.13 ± 14.79 | h1 = 94.85 ± 15.45; h2 = 97.35 ± 19.66; h3 = 94.91 ± 17.36 | h1 = 92.53 ± 16.53; h2 = 102.87 ± 19.51; h3 = 105.47 ± 16.60 | NR | NR | NR | NR |
| Soliman et al[25], 2017 | NR | NR | NR | NR | 85.3 ± 6.9 | 85.1 ± 6.6 | No different time points. 79.9 ± 7.5 | 79.0 ± 6.9 | NR | NR | NR | NR |
| Kumar et al[26], 2020 | NR | NR | NR | NR | Immediate postinduction = 83.6 ± 11.7, 3 minutes = 70.1 ± 6.8, 1 minute postintubation = 101.4 ± 13.1, 3 minutes = 90.4 ± 14.2, 5 minutes = 85.3 ± 14.7, 10 minutes = 83.5 ± 14.5 | Immediate postinduction = 90.4 ± 8.8, 3 minutes = 85.2 ± 8.0, 1 minute postintubation = 92.7 ± 7.7, 3 minutes = 89.2 ± 6.5, 5 minutes = 89.2 ± 6.2, 10 minutes = 88.1 ± 6.0 | Immediate postinduction = 79.2 ± 8.6, 3 minutes = 65.7 ± 5.4, 1 minute postintubation = 103.5 ± 12.4, 3 minutes = 94.1 ± 8.9, 5 minutes = 86.9 ± 9.4, 10 minutes = 81.3 ± 9.9 | Immediate postinduction = 82.2 ± 11.3, 3 minutes = 80.8 ± 12.4, 1 minute postintubation = 84.8 ± 9.5, 3 minutes = 88.0 ± 15.8, 5 minutes = 84.6 ± 15.4, 10 minutes = 82.2 ± 15.0 | NR | NR | NR | NR |
| Andolfatto et al[18], 2012 | NR | NR | NR | NR | NR | NR | NR | NR | 14 ± 10 | 5 ± 4 | NR | NR |
| Tandon et al[24], 2014 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Khalil et al[35], 2021 | NR | NR | NR | NR | T1 = 115, T2 = 110, T3 = 105, T4 = 100, T5 = 95, T6 = 90 | T1 = 110; T2 = 105; T3 = 100; T4 = 95; T5 = 90; T6 = 85 | T1 = 105; T2 = 100; T3 = 95; T4 = 90; T5 = 85; T6 = 80 | T1 = 85; T2 = 90; T3 = 85; T4 = 80; T5 = 75; T6 = 70 | NR | NR | NR | NR |
| Frey et al[23], 1999 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Cui et al[27], 2023 | NR | NR | NR | NR | t1 = 100; t2 = 100; t3 = 85; t4 = 83; t5 = 80; t6 = 83; t7 = 84; t8 = 83 | t1 = 100; t2 = 99; t3 = 89; t4 = 85; t5 = 84; t6 = 86; t7 = 89; t8 = 89 | NR | NR | NR | NR | 0 | 1 ± 1.5 |
| Liu et al[28], 2025 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 2 ± 1.6 | 3 ± 2.4 |
| Zheng et al[29], 2023 | t1 = 124; t2 = 110; t3 = 103; t4 = 140; t5 = 120 | t1 = 123; t2 = 120; t3 = 120; t4 = 124; t5 = 125 | t1 = 71; t2 = 65; t3 = 60; t4 = 76; t5 = 69 | t1 = 70; t2 = 69; t3 = 68; t4 = 70; t5 = 69 | NR | NR | t1 = 75; t2 = 70; t3 = 68; t4 = 83; t5 = 75 | t1 = 75; t2 = 74; t3 = 73; t4 = 77; t5 = 75 | NR | NR | NR | NR |
| Fu et al[19], 2024 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Beyoğlu et al[33], 2020 | 84.5 ± 9.9 | 85.2 ± 14.4 | 48.8 ± 9.1 | 52.1 ± 6.9 | NR | NR | NR | NR | NR | NR | NR | NR |
| Frizelle et al[21], 1997 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Bhardwaj et al[30], 2024 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Schmitz et al[31], 2018 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Chiaretti et al[20], 2011 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Xu et al[43], 2024 | 0 minute = 109; 5 minutes = 99; 10 minutes = 100; 15 minutes = 102; 20 minutes = 101; 25 minutes = 104; 30 minutes = 107; 35 minutes = 104; 40 minutes = 102; 45 minutes = 98; 50 minutes = 97; 55 minutes = 97; 60 minutes = 97 | 0 minute = 42; 5 minutes = 42; 10 minutes = 42; 15 minutes = 42; 20 minutes = 40; 25 minutes = 40; 30 minutes = 33; 35 minutes = 25; 40 minutes = 19; 45 minutes = 15; 50 minutes = 12; 55 minutes = 11; 60 minutes = 11 | 0 minute = 66; 5 minutes = 55; 10 minutes = 58; 15 minutes= 62; 20 minutes = 63; 25 minutes = 64; 30 minutes = 62; 35 minutes = 62; 40 minutes = 60; 45 minutes = 58; 50 minutes = 55; 55 minutes = 52; 60 minutes = 43 | 0 minute = 64; 5 minutes = 56; 10 minutes = 67; 15 minutes = 54; 20 minutes = 66; 25 minutes = 51; 30 minutes = 61; 35 minutes = 61; 40 minutes = 59; 45 minutes = 54; 50 minutes = 50; 55 minutes = 51; 60 minutes = 50 | NR | NR | NR | NR | NR | NR | NR | NR |
Table 4 Summary of meta-regression findings for hypotension outcome, showing direction and approximate trend of associations between covariates (propofol dosage, mean age, and ketamine dosage) and log risk ratio
| Covariate (moderator) | Direction of association | Approximate trend |
| Propofol dosage difference (msg) | Positive | Each 50 mg increase in propofol appeared to increase LogRR by approximately 0.05-0.10 |
| Mean age (years) | Slighty negative | Each approximately 10 years increase in mean age appeared to decrease LogRR by approximately 0.01 (very weak) |
| Ketamine dosage difference | Negative | Each 50 mg increase in ketamine appeared to decrease LogRR by approximately 0.05-0.08 |
- Citation: Faheem MSB, Hassan ST, Feroze F, Khan A, Munir SU, Khaliq A, Fatima ST, Mendonca R, Surani S. Combination of N-methyl-D-aspartate receptor antagonists and propofol for procedural sedation. World J Clin Cases 2026; 14(8): 118582
- URL: https://www.wjgnet.com/2307-8960/full/v14/i8/118582.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v14.i8.118582
